HPV16 CTL Epitope Peptide-activated Dendritic Cell and Natural Killer Co-culture for Therapy of Cervical Cancer in an Animal Model

  • Hu, Yan-Xia (Department of Gynecology and Obstetrics, Henan University of Traditional Chinese Medicine) ;
  • Li, Min (Department of Oncology, People's Hospital of Zhengzhou, Henan University of Traditional Chinese Medicine) ;
  • Jia, Xiao-Hui (Department of Gynecology and Obstetrics, Henan University of Traditional Chinese Medicine) ;
  • Du, Qu-Xiao (Department of Gynecology and Obstetrics, Henan University of Traditional Chinese Medicine) ;
  • Miao, Feng-Tai (Department of Gynecology and Obstetrics, Henan University of Traditional Chinese Medicine) ;
  • Yao, Li (Department of Gynecology and Obstetrics, Henan University of Traditional Chinese Medicine) ;
  • Shen, Ji-Duo (College of Pharmacy, Henan University of Traditional Chinese Medicine)
  • Published : 2013.12.31


There is increasing evidence that natural killer (NK) cells play an important role in antitumor immunity following dendritic cell (DC) vaccination. Little is known, however, about the optimal stimulation of DCs by epitopes and NK interactions for cytotoxicity in tumors. In this study, DC cells activated by the HPV16E7.49-57 epitope and LPS were co-cultured with NK cells in vitro, and then used ot immunize mice to study CTL activity of TC-1, which constitutively expresses HPV16E6E7, with an LDH release assay. Cytotoxicity in mice immunized with DC loaded with epitope HPVE7.49-57 vaccine co-cultured with NK was enhanced significantly (p<0.01). In conclusion, talk-across between DC and NK cells enhances their functions, also improving cytotoxicity againsttumor cells, suggesting that activated DC-NK by epitopes has potential application for cancer-specific immuno-cellular therapy.


  1. Degli-Esposti MA, Smyth MJ (2005). Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol, 5, 112-24.
  2. Di Nicola M, Zappasodi R, Carlo-Stella C, et al (2009). Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood, 113, 18-27.
  3. Eissmann P, Evans JH, Mehrabi M, et al (2010). Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk. J Immunol, 184, 6901-9.
  4. Gasser S, Raulet D (2006). The DNA damage response, immunity and cancer. Semin Cancer Biol, 16, 344-7.
  5. Bellora F, Castriconi R, Dondero A, et al (2010). The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci USA, 107, 21659-64.
  6. Boudreau JE, Bridle BW, Stephenson KB, et al (2009). Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther, 17, 1465-72.
  7. Gilboa E (2007). DC-based cancer vaccines. J Clin Invest, 117, 1195-203.
  8. Grzywacz B, Miller JS, Verneris MR (2008). Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol, 21, 467-83.
  9. Ilett EJ, Prestwich RJ, Melcher AA. (2010). The evolving role of dendritic cells in cancer therapy. Expert Opin Biol Ther, 10, 369-79.
  10. Karimi K, Boudreau JE, Fraser K, et al (2008). Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gammaproducing NK cells. Mol Ther, 16, 411-8.
  11. Morandi B, Mortara L, Chiossone L, et al (2012). Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS One, 7, e39170.
  12. Nakai N, Hartmann G, Kishimoto S, et al (2010). Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res, 23, 607-19.
  13. Osada T, Clay T, Hobeika A, et al (2006). NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother, 55, 1122-31.
  14. Petersen TR, Sika-Paotonu D, Knight DA, et al (2011). Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines. PLoS One, 6, e17657.
  15. Shanker A (2010). Adaptive control of innate immunity. Immunol Lett, 131, 107-12.
  16. Shanker A, Buferne M, Schmitt-Verhulst AM (2010). Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology, 129, 41-54.
  17. Shanker A, Verdeil G, Buferne M, et al (2007). CD8 T cell help for innate antitumor immunity. J Immunol, 179, 6651-62.
  18. Shen L, Evel-Kabler K, Strube R, et al (2004). Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol, 22, 1546-53.
  19. van den Broeke LT, Daschbach E, Thomas EK, et al (2003). Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol, 171, 5842-52.
  20. Van Elssen CH, Vanderlocht J, Oth T, et al (2011). Inflammationrestraining effects of prostaglandin E2 on natural killerdendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood, 118, 2473-82.
  21. Viaud S, Terme M, Flament C, et al (2009). Dendritic cellderived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One, 4, e4942.

Cited by

  1. Preliminary Evaluation of the in vitro Efficacy of 1, 2-di (Quinazolin-4-yl) Diselane against SiHa Cervical Cancer Cells vol.15, pp.15, 2014,
  2. Interleukin-18 Synergism with Interleukin-2 in Cytotoxicity and NKG2D Expression of Human Natural Killer Cells vol.15, pp.18, 2014,
  3. Tumor-derived CD4+CD25+ Tregs Inhibit the Maturation and Antigen-Presenting Function of Dendritic Cells vol.16, pp.7, 2015,
  4. Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide vol.33, pp.5, 2015,